Active vitamin D analog and SARS‐CoV‐2 IgG after BNT162b2 vaccination in patients with hemodialysis: Correspondence

Abstract

Dear Editor, We would like to share ideas on the publication. "Active vitamin D analog and severe acute respiratory syndrome coronavirus immunoglobulin G (SARS-CoV-2 IgG) after BNT162b2 vaccination in patients with hemodialysis" [1]. The purpose of the study was to look at the relationship between active vitamin D analogs and SARS-CoV-2 IgG levels in hemodialysis patients who had received the BNT162b2 (Pfizer©) coronavirus disease 2019 (COVID-19) vaccine. The usage of active vitamin D analog was linked, according to the results, to increased levels of SARS-CoV-2 IgG from the time of vaccination to 90 days afterward. Nearly two-thirds of the 418 participants in the study-whose mean age was 71.1 years-were administered active vitamin D analogs.This research concentrated on hemodialysis patients, a group recognized to be more vulnerable to severe COVID-19 consequences. Examining the relationship between SARS-CoV-2 IgG levels and the usage of active vitamin D analogs, the study shed light on possible vaccination-induced immune responses in this population. Blood samples were taken at various intervals prior to and during immunization, enabling a thorough examination of alterations in SARS-CoV-2 IgG levels in connection with the use of active vitamin D analogs. The findings imply that the use of active vitamin D analogs may be associated with increased SARS-CoV-2 IgG levels, which may have implications for hemodialysis patients' immunization plans.The absence of a control group in the study could be a possible issue. It is difficult to assess if the observed correlation between the use of active vitamin D analogs and increased SARS-CoV-2 IgG levels is actually a causal relationship in the absence of a comparison group of hemodialysis patients who did not get these supplements. Furthermore, other complicating factors such comorbidities or medication interactions that can affect SARS-